Transcript Membranes Used in Drug Delivery

Membranes Used in Drug Delivery
Walter Trachim
BMCB658
3/2/12
Introduction

Membrane-based drug delivery systems have
been developed for a number of reasons
Size
 Timing
 Bioavailability


Different types of delivery systems exist and are
used in different applications
Membrane- Based Delivery

A number of different membrane-based delivery
systems exist. They include:
Liposome
 Liposome/Nanoparticle Hybrid
 PLGA

Delivery Systems


Liposomes – Single or multiple lipid bi-layers
arranged in concentric circles designed to
contain an aqueous solution
Reliable :
Biocompatible
 Biodegradable
 Can be scaled, or their size can be modified
 Considerably lower toxicity levels

Delivery Systems


PLGA – Polylactide-co-glycolide
Pros
Biocompatible
 Versatile – will encapsulate a wide variety of
medications
 Able to “tune” how drug is released


Cons
Can be inefficient at low pH
 Degraded easily in acid environments

Membrane-Based Delivery

Liposome-Nanoparticle Hybrids
Can be hydrophilic (encapsulated in the liposome) or
hydrophobic (embedded in the lipid bilayer)
 Used primarily for diagnostic testing – imaging is a
common application (PET, MRI)
 Also used for chemotherapy, mainly as a guard
against cytotoxicity

Membrane-Based Delivery

Liposome – Quantum Dot Hybrids

Semiconductors – have fluorescent qualities

Used for optically-based diagnostic applications

Also used for chemotherapy – less prone to leakage

LD50 found to be favorable for pulmonary imaging
Applications



Cancer treatment – chemotherapy
Pain management
Time-release
Anti-hypertensives
 Anti-depressants
 Sleep aids

References



Al-Jamal, W., & Kostarelos, K. (2011). Liposomes: From a
Clinically Established Drug Delivery System to a Nanoparticle
Platform for Theranostic Nanomedicine. Accounts of Chemical
Research, 44(10), 1094-1104. doi:10.1021/ar200105p
Samstein, R., Perica, K., Balderrama, F., Look, M., Fahmy, T.
(2007). The use of deoxycholic acid to enhance the oral
bioavailability of biodegradable nanoparticles. Biomaterials, 29,
703-708. doi:10.1016/j.biomaterials.2007.10.026
Wieber, A., Selzer, T., Kreuter, J. (2011). Characterisation and
stability studies of a hydrophilic decapeptide in different
adjuvant drug delivery systems: A comparative study of PLGA
nanoparticles versus chitosan-dextran sulphate micriparticles
versus DOTAP-liposomes. International Journal of Pharmaceutics,
421, 151-159. doi:/10.1016.j.ijpharm.2011.09.011